Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Protalex Inc. (PRTX : OTCBB)
 
 • Company Description   
Protalex, Inc. is a biopharmaceutical company. It focused on the development of drugs for treating autoimmune and inflammatory diseases, including rheumatoid arthritis and other forms of arthritis. Protalex, Inc. is based in Summit, New Jersey.

Number of Employees:

 
 • Price / Volume Information   
Yesterday's Closing Price: $ Daily Weekly Monthly
20 Day Moving Average: shares
Shares Outstanding: (millions)
Market Capitalization: $ (millions)
Beta:
52 Week High: $
52 Week Low: $
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week % %
12 Week % %
Year To Date % %
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
131 COLUMBIA TURNPIKE SUITE 1
-
FLORHAM PARK,NJ 07932
USA
ph: 215-862-9720
fax: 215-862-6614
afields@lhai.com http://www.protalex.com
 
 • General Corporate Information   
Officers
Arnold P. Kling - President and Director
Kirk M. Warshaw - Chief Financial Officer and Director
Marco M. Elser - Director
Eugene A. Bauer - Director
Frank M. Dougherty - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 743642209
SIC: 8731
Fiscal Year
Fiscal Year End: May
Last Reported Quarter: -
Next Expected EPS Date: -
Share - Related Items
Shares Outstanding:
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $ (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: %
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: -  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
05/31/25 - -
02/28/25 - -
11/30/24 - -
ROA
05/31/25 - -
02/28/25 - -
11/30/24 - -
Current Ratio
05/31/25 - -
02/28/25 - -
11/30/24 - -
Quick Ratio
05/31/25 - -
02/28/25 - -
11/30/24 - -
Operating Margin
05/31/25 - -
02/28/25 - -
11/30/24 - -
Net Margin
05/31/25 - -
02/28/25 - -
11/30/24 - -
Pre-Tax Margin
05/31/25 - -
02/28/25 - -
11/30/24 - -
Book Value
05/31/25 - -
02/28/25 - -
11/30/24 - -
Inventory Turnover
05/31/25 - -
02/28/25 - -
11/30/24 - -
Debt-to-Equity
05/31/25 - -
02/28/25 - -
11/30/24 - -
Debt-to-Capital
05/31/25 - -
02/28/25 - -
11/30/24 - -
 

Powered by Zacks Investment Research ©